IGF1R Protein Expression is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2-positive Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831

BACKGROUND: Preclinical evidence indicates that increased insulin-like growth factor receptor-1 (IGF1R) signaling interferes with the action of trastuzumab suggesting a possible mechanism of trastuzumab resistance. Thus, we evaluated IGF1R prevalence, relationship with demographic data, and associat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Reinholz, Monica M., Chen, Beiyun, Dueck, Amylou C., Tenner, Kathleen, Ballman, Karla, Riehle, Darren, Jenkins, Robert B., Geiger, Xochiquetzal J., McCullough, Ann E, Perez, Edith A.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5769872/
https://ncbi.nlm.nih.gov/pubmed/28533226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0574
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares